Heparin is given parenterally and unfractionated heparin (UFH) has a half-life of about one to two hours after infusion. The half-life of low-molecular-weight heparin (LMWH) is about four to eight hours. Heparin is obtained naturally from mucosal tissues of slaughtered meat animals such as porcine intestines or bovine lungs or prepared synthetically.
Europe heparin market is estimated to account for US$ 4,085.8 Mn in terms of value by the end of 2027.
Europe Heparin Market: Drivers
Increasing prevalence of venous thromboembolism (VTE) is expected to propel growth of Europe heparin market over the forecast period. For instance, according to NHS Scotland’s 2018 report, 75,846 people were admitted to hospital for VTE in Scotland from 2008 to 2017.
Europe Heparin Market: Opportunities
Potential of LMWH in reducing lung injury is expected to offer lucrative growth opportunities for players in Europe heparin market. For instance, in April 2020, researchers from Chang Gung Memorial Hospital, Taiwan, reported that LMWH reduced ventilation-induced lung injury through hypoxia inducible factor-1α in a murine endotoxemia model.
Europe Heparin Market: Restraints
Risk of heparin induced thrombocytopenia is expected to hinder growth of the market. Heparin-induced thrombocytopenia (HIT) is a complication of heparin therapy. There are two types of HIT: type 1 and type 2. Type 1 HIT occurs within two days of heparin therapy, while type 2 is observed within 4 days to 10 days of heparin therapy.
Europe heparin market was valued at US$ 2,698.7 Mn in 2019 and is forecast to reach a value of US$ 4,085.8 Mn by 2027 at a CAGR of 6.1% between 2020 and 2027. Increasing prevalence of venous thromboembolism (VTE) is expected to propel growth of Europe heparin market over the forecast period
Low Molecular Weight Heparin segment held dominant position in Europe heparin market in 2019, accounting for 81.4% share in terms of value, followed by Ultra Low Molecular Weight Heparin. Increasing demand for Low Molecular Weight Heparin in reducing lung injury is expected to drive the market growth.
Increasing prevalence of chronic kidney disease is boosting growth of the market. For instance, according to the study, ‘Prevalence and deaths for chronic kidney disease in 2017, and percentage change of age-standardized rates by location, 1990–2017’ published in February 2020, U.K. recorded around 5,636,676 cases of chronic kidney disease in 2017.
Major players in the market are sourcing active pharmaceutical ingredients from Europe. For instance, in November 2019, Fresenius Kabi launched preservative-free Heparin Sodium Injection, USP in 5,000 USP units per 0.5 mL in Simplist ready-to-administer prefilled syringes, in the U.S. The drug’s active pharmaceutical ingredient is sourced from Europe.
Europe Heparin Market: Competitive Landscape
Major players operating in Europe heparin market include, Pfizer, Inc., Sagent Pharmaceuticals, Inc., B. Braun Melsungen AG, Baxter International Inc., GlaxoSmithKline plc, Bayer AG, Anselm Pharmaceuticals, Bristol-Myers Squibb Co., Dr. Reddy’s Laboratories Ltd., Fresenius SE & Co. KGaA, Leap Labchem Co., LEO Pharma A/S, Sanofi S.A., Syntex S.A., Teva Pharmaceutical Industries Ltd., United Biotech (P) Ltd, Amphastar Pharmaceuticals Inc., Abbott Laboratories, Aspen Pharmacare Holdings, Laboratorios Farmaceuticos ROVI SA, and Intrapharm Laboratories.
Europe Heparin Market: Key Developments
Major players in the market are focused on adopting collaboration strategies to expand their product portfolio. For instance, in September 2019, Nichi-Iko Pharmaceutical, the parent company of Sagent Pharmaceuticals, Inc., collaborated with Eisai Co., Ltd. for the generic pharmaceutical business in China.
Scope of the report